Sanara Medtech Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -7.1% | +56.0% | +2.1% | +37.2% | +265.5% | -11.6% | +270.4% | +67.7% | +21.0% | +19.3% | -17.2% | |
| – | -4.3% | +72.3% | +2.1% | -52.0% | +805.0% | -49.4% | +449.0% | -16.2% | -7.8% | +75.2% | +0.7% | |
| – | -65.2% | +357.1% | -44.4% | +58.0% | +803.5% | -93.1% | +3,996.2% | -52.0% | -42.5% | +208.5% | +4.4% | |
| – | -65.2% | +357.1% | -44.4% | +58.0% | +803.5% | -93.1% | +3,996.2% | -52.0% | -42.5% | +208.5% | +4.4% | |
| – | +62.6% | +75.5% | +5.3% | -74.3% | +522.0% | +69.8% | +31.9% | +134.2% | +21.8% | +58.8% | -11.5% | |
| – | +1.8% | -15.0% | +104.2% | -34.6% | +60.4% | +53.8% | +78.4% | +73.3% | +32.9% | -41.6% | +43.4% | |
| – | – | -16.3% | +80.9% | -70.3% | +4,108.4% | +45.1% | +78.2% | -30.7% | – | – | – | |
| – | – | – | – | – | – | – | – | – | +0.0% | +0.0% | +0.0% | |
| – | -21.1% | -26.7% | -16.4% | -55.4% | +2,714.8% | +110.6% | +52.6% | +566.5% | +42.6% | -8.7% | -54.5% | |
| – | +14.6% | -2.6% | -18.5% | -8.8% | +144.8% | -15.6% | +56.7% | +209.3% | +51.6% | +67.9% | +36.3% | |
| – | -37.0% | -4.4% | +51.7% | -80.9% | +553.4% | +34.1% | +70.1% | +112.6% | +7.5% | +11.1% | +21.8% | |
| – | -61.2% | -31.9% | +184.4% | -99.1% | +1,022.1% | +6.9% | +61.9% | +54.4% | +199.9% | -61.9% | -1.5% | |
| – | +5.7% | +7.1% | -5.4% | -76.0% | +649.7% | +21.8% | +20.0% | +140.2% | +40.3% | -25.1% | +55.9% | |
| – | – | +0.0% | – | – | +0.0% | – | – | – | – | +236.8% | +49.8% | |
| – | – | – | – | +984.5% | +494.8% | -7.0% | +398.2% | +36.5% | +7.2% | -12.1% | -85.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.7% | +2.3% | +90.2% | +4.1% | -1.8% | +168.9% | +28.0% | +7.7% | +4.7% | +2.5% | +1.6% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.